Efficacy and suicidal risk for antidepressants in paediatric and adolescent patients

Statistical Methods in Medical Research

Volumn 22, Issue 2, 2013, Pages 190-218

  Julious, Steven A ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Efficacy; meta analysis; SSRIs; suicide

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; DEPRESSION; DRUG EFFICACY; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUICIDAL BEHAVIOR; SUICIDAL IDEATION;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CHILD; DEPRESSION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SELF-INJURIOUS BEHAVIOR; SUICIDAL IDEATION; SUICIDE, ATTEMPTED;

EID: 84876741000     PISSN: 09622802     EISSN: 14770334     Source Type: Journal    
DOI: 10.1177/0962280211432210     Document Type: Article

References (79)

1. FDA. Relationship between psychotropic drugs and pediatric suicidality: review and evaluation of clinical data, http://www.fda.gov/ohrms/dockets/ac/04/ briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf (2004, accessed 24 October 2011).
2. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006 ; 63: 246-248
3. Kaizar EE, Greenhousea JB, Seltmana H, Kelleherc K. Do antidepressants cause suicidality in children? A Bayesian meta-analysis. Clin Trials. 2006 ; 3: 73-98
4. Cheung AH, Emslie GJ, Mayes TL. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry. 2005 ; 46 (7). 735-754 (Pubitemid 40932958)
5. Cheung AH, Emslie GJ, Mayes TL. The use of antidepressants to treat depression in children and adolescents. CMAJ. 2006 ; 174 (2). 193-200 (Pubitemid 43166275)
6. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004 ; 363: 1341-1345 (Pubitemid 38529872)
7. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA. 2004 ; 292: 338-343 (Pubitemid 38944257)
8. FDA. Revisions to product labeling, http://www.fda.gov/downloads/Drugs/ DrugSafety/InformationbyDrugClass/UCM173233.pdf (2004, accessed 24 October 2011).
9. Committee on the Safety of Medicines. Report of the CSM expert working group on the safety of selective serotonin reuptake inhibitor antidepressants, http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con019472. pdf (2004, accessed 24 October 2011).
10. Gunnell D, Saperia J, Ashby D. Selective Serotonin Reuptake Inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ. 2005 ; 330: 385-385
11. Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ. 2005 ; 330: 389-393 (Pubitemid 40288823)
12. Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007 ; 297: 1683-1696
13. Hazell P, O'Connell D, Heathcote D and Henry DA. Tricyclic drugs for depression in children and adolescents (Review). Cochrane Database Syst Rev 2002; (2): Art. No.: CD002317. DOI: 10.1002/14651858.CD002317.
14. Tsapakis EM, Soldani F, Tondo L, Baldessarin RJ. Efficacy of antidepressants in juvenile depression: meta-analysis. Br J Psychiatry. 2008 ; 193: 10-17 (Pubitemid 351946803)
15. 110th US Congress. Public Law 110-85, http://frwebgate.access.gpo.gov/ cgi-bin/getdoc.cgi?dbname=110-cong-public-laws&docid=f:publ085.110 (2007, accessed 24 October 2011).
16. Food and Drug Administration. Food and Drug Administration Modernization Act (FDAMA) of 1997, http://www.fda.gov/RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDAMA/ default.htm (1997, accessed 24 October 2011).
17. FDA/Center for Drug Evaluation and Research. Guidance for industry information program on clinical trials for serious or life-threatening diseases and conditions, http://www.fda.gov/downloads/regulatoryinformation/guidances/ ucm126838.pdf (2002, accessed 24 October 2011).
18. Uniform requirements for manuscripts submitted to biomedical journals. Lancet. 2004 ; 364: 911-912
19. IFPMA. Joint position on the disclosure of clinical trial information via clinical trial registries and databases, updated November 2008, http://clinicaltrials.ifpma.org/fileadmin/files/pdfs/EN/Revised-Joint-Industry- Position-Nov-2008.pdf (2008, accessed 24 October 2011).
20. UKMi. Evaluated information for the NHS: escitalopram, http://www.ukmi.nhs.uk/NewMaterial/html/docs/escitalopram.pdf (2002, accessed 24 October 2011).
21. Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA. 2003 ; 290: 1033-1041 (Pubitemid 37430443)
22. Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y. Venlafaxine ER for the treatment of pediatric subjects with depression: results of 2 placebo-controlled trials. J Am Acad Child Adolesc Psychiatry. 2007 ; 46: 479-488 (Pubitemid 46622756)
23. Rynn MA, Riddle MA, Yeung PP, Kunz NR. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am J Psychiatry. 2007 ; 164: 290-300
24. Julious SA Sample sizes for clinical trials. London, England: Chapman and Hall ; 2010 :
25. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998 ; 17: 873-890 (Pubitemid 28185166)
26. Whitehead A Meta-analysis of controlled clinical trials. Chichester: Wiley ; 2002 :
27. Hardy RF, Thompson SG. Detecting and describing heterogeneity in meta analysis. Stat Med. 1998 ; 17: 841-856 (Pubitemid 28185164)
28. Julious SA and Whitehead A. Investigating the assumption of homogeneity of treatment effects in clinical studies with application to meta-analysis. Pharm Stat DOI: 10.1002/pst.494.
29. Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry. 2001 ; 158: 2008-2014 (Pubitemid 33104106)
30. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al. Treatment for Adolescents With Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004 ; 292: 807-820
31. Pfizer. A multicenter, 10-week, randomized, double-blind study of sertraline and placebo in children and adolescents with Posttraumatic Stress Disorder (PTSD), http://www.clinicalstudyresults.org/documents/company-study- 2909-0.pdf (2008, accessed 24 October 2011).
32. Pfizer. Sertraline in the treatment of Obsessive Compulsive Disorder (OCD), http://www.clinicalstudyresults.org/documents/company-study-1595-0.pdf (2006, accessed 24 October 2011).
33. Chuang-Stein C, Beltangady M. Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies. Pharm Stat. 2011 ; 10 (1). 3-7
34. Rucker G and Schumacher M. Simpson's Paradox visualized: the example of the Rosiglitazone meta-analysis. BMC Med Res Methodol 2008; 8: 34. http://www.biomedcentral.com/1471-2288/8/34 (2008, accessed 24 October 2011).
35. Julious SA, Mullee MA. Confounding and Simpson's Paradox. Br Med J. 1994 ; 309 (6967). 1480-1481 (Pubitemid 24360989)
36. Julious SA, Wang SJ. Issues with indirect comparisons in clinical trials particularly with respect to non-inferiority trials. Drug Inf J. 2008 ; 42 (6). 625-633
37. The Pediatric OCD Treatment Study Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA. 2004 ; 292: 1969-1976
38. Liebowitz MR, Turner SM, Piacentini J, Beidel DC, Clarvit SR, Davies SO, et al. Fluoxetine in children and adolescents with OC: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2002 ; 41: 1431-1438 (Pubitemid 44698519)
39. Birmaher B, Axelson DA, Monk K, Kalas C, Clark DB, Ehmann M, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2003 ; 42: 415-423 (Pubitemid 39625076)
40. Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008 ; 359 (26). 2753-2766
41. RUPP. Research Unit on Pediatric Psychopharmacology Anxiety Study Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med. 2001 ; 344: 1279-1285
42. Forest. A double blind placebo controlled evaluation of the safety and efficacy of escitalopram in pediatric depression, http://www. forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?-file-id=scsr/ SCSR-SCT-MD-15-final.pdf (2008, accessed 24 October 2011).
43. Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry. 2006 ; 45: 280-288
44. Forest. A double blind flexible dose study of escitalopram in pediatric with major depressive disorder, http://www.forestclinicaltrials.com/CTR/ CTRController/CTRViewPdf?-file-id=scsr/SCSR-SCT-MD-32-final.pdf (2005, accessed 24 October 2011).
45. March JS, Entsuah AR, Rynn M, Albano AM, Tourian KA. A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry. 2007 ; 62: 1149-1154 (Pubitemid 350029720)
46. Eli Lilly. Fluoxetine versus placebo in the acute treatment of major depressive disorder in children and adolescents, http://www. clinicalstudyresults.org/documents/company-study-152-0.pdf (2004, accessed 24 October 2011).
47. Simeon JG, Dinicola VF, Ferguson HB, Copping W. Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry. 1990 ; 14: 791-795
48. Eli Lilly. Fluoxetine versus placebo in the acute treatment of major depressive disorder in children and adolescents, http://www. clinicalstudyresults.org/documents/company-study-153-0.pdf (2004, accessed 24 October 2011).
49. Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997 ; 54: 1031-1037 (Pubitemid 27476099)
50. Eli Lilly. Fuoxetine versus placebo in childhood/adolescent depression, http://www.clinicalstudyresults.org/documents/company-study-154-0.pdf (2004, accessed 24 October 2011).
51. Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002 ; 41: 1205-1215 (Pubitemid 38338040)
52. Eli Lilly. Fluoxetine versus placebo in the treatment of children and adolescents with obsessive-compulsive disorder, http://pdf.clinicalstudyresults. org/documents/company-study-155-0.pdf (2004, accessed 24 October 2011).
53. Geller DA, Hoog SL, Heiligenstein JH, et al. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry. 2001 ; 40: 773-779 (Pubitemid 32595261)
54. March JS, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook EH, et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA. 1998 ; 280 (20). 1752-1756 (Pubitemid 28536875)
55. Pfizer. Written testimony of Pfizer Inc submitted to the House Committee on Energy and Commerce Subcommittee on oversight and investigations regarding Zoloft studies in the pediatric population, http://archives.energycommerce. house.gov/reparchives/108/Hearings/09092004hearing1351/Clary2207.htm (2004, accessed 24 October 2011).
56. Pfizer. A multi-center 10-week randomized double-blind placebo-controlled flexible dose outpatient study of sertraline in children and adolescents with major depressive disorder, http://www.clinicalstudyresults.org/documents/ company-study-98-0.pdf (2004, accessed 24 October 2011).
57. Pfizer. Two multicenter 10-week randomized double-blind placebo-controlled flexible dose outpatient studies of sertraline in children and adolescents with major depressive disorder combined, http://www. clinicalstudyresults.org/documents/company-study-98-1.pdf (2004, accessed 24 October 2011).
58. MHRA. Selective Serotonin Reuptake Inhibitors (SSRIs): overview of regulatory status and CSM advice relating to Major Depressive Disorder (MDD) in children and adolescents including a summary of available safety and efficacy data, http://www.mhra.gov.uk/PrintPreview/DefaultSP/CON019494 (2005, accessed 24 October 2011).
59. Pfizer. A multicenter 10-week randomized double-blind placebo-controlled flexible dose outpatient study of sertraline in children and adolescents with major depressive disorder, http://www.clinicalstudyresults.org/documents/ company-study-1981-0.pdf (2004, accessed 24 October 2011).
60. GSK. A multi-center, double-blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression- acute phase, http://www.gsk.com/media/paroxetine/depression-329-full.pdf (1998, accessed 24 October 2011).
61. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001 ; 40: 762-772 (Pubitemid 32595260)
62. GSK. A double-blind, multicentre placebo controlled study of paroxetine in adolescents with unipolar major depression, http://www.gsk.com/media/ paroxetine/depression-377-full.pdf (1998, accessed 24 October 2011).
63. Berard R, Fong R, Carpenter DJ, Thomason C, Wilkinson C. An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2006 ; 16: 59-75
64. GSK. A 16 week double-blind, placebo controlled study to investigate the efficacy and tolerability of paroxetine in the treatment of children and adolescents with social anxiety disorder/social phobia, http://www.gsk.com/ media/paroxetine/sad-676-full.pdf) (2002, accessed 24 October 2011).
65. Wagner KD, Berard R, Stein MB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry. 2004 ; 61: 1153-1162 (Pubitemid 39463417)
66. GSK. A randomized, multicenter, 8-week, double-blind, placebo-controlled flexible-dose study to evaluate the efficacy and safety of paroxetine in children and adolescents with major depressive disorder, http://www.gsk.com/ media/paroxetine/depression-701-full.pdf (2001, accessed 24 October 2011).
67. Emslie GJ, Wagner KD, Kutcher S, et al. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2006 ; 45: 709-719 (Pubitemid 43833104)
68. GSK. A randomized, multicenter, 10-week, double-blind, placebo-controlled, flexible-dose study to evaluate the efficacy and safety of paroxetine in children and adolescents with Obsessive-Compulsive Disorder (OCD), http://www.gsk.com/media/paroxetine/ocd-704-full.pdf (2001, accessed 24 October 2011).
69. Geller DA, Wagner KD, Emslie G, et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2004 ; 43: 1387-1396 (Pubitemid 39411039)
70. FDA. Clinical review of luvox (fluvoxamine). NDA 20-243 pediatric supplement S-021, http://www.accessdata.fda.gov/drugsatfda-docs/nda/2000/20- 243S021.pdf (2000, accessed 24 October 2011).
71. Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghorn JL, Gaffney G, et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry. 2001 ; 40: 222-229 (Pubitemid 32111026)
72. FDA. Review and evaluation of clinical data for celexa. (citalopram hydrocloride). NDA 20-822 pediatric supplement SE5-016, http://www.fda.gov/ downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM162562.pdf) (2002, accessed 24 October 2011).
73. Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry. 2006 ; 45: 280-288
74. von Knorring AL, Olsson GI, Thomsen PH, Lemming OM, Hulten A. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J Clin Psychopharmacol. 2006 ; 26: 311-315 (Pubitemid 43804624)
75. Casat CD, Pleasants DZ, Van Wyck Fleet J. A double-blind trial of bupropion in children with attention deficit disorder. Psychopharmacol Bull. 1987 ; 23 (1). 120-122 (Pubitemid 17111676)
76. Conners CK, Casat CD, Gualtieri CT, Weller E, Reader M, Reiss A, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Adolesc Psychiatry. 1996 ; 34 (10). 1314-1321 (Pubitemid 26327705)
77. FDA. Clinical review for effexor XR. NDA 20-151 paediatric supplement SE5-024, http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ DevelopmentResources/UCM163132.pdf (2003, accessed 24 October 2011).
78. FDA. Review and evaluation of clinical data: nefazodone hydrochloride (serzone). NDA: 20-152 pediatric supplement S-032, http://www.fda.gov/downloads/ Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM164073.pdf (2002, accessed 24 October 2011).
79. FDA. Review and evaluation of clinical data: mirtazapine (remeron). NDA 20-415 pediatric supplement SE5-011, http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/UCM164066.pdf) (2001, accessed 24 October 2011).